Senior Director, PM Portfolio Lead, Cell Therapy at Bristol-Myers Squibb

Boudry, Neuchatel, Switzerland

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, PharmaceuticalsIndustries

Requirements

Provide line management leadership, coaching, and development for up to 10 Program Management (PM) team members
Oversee program and project execution for a specific therapeutic area portfolio (or subset)
Serve as a business partner to Global Franchise Leads and Therapeutic Area Head (directly and in partnership with Portfolio Strategy and Operations Leads)
Potentially serve as an interim Program Management Lead for an asset, operating as a strategic partner to the Global Program Lead (GPL)
Prioritize time for overseeing execution of therapeutic area portfolio and personnel line management
Act as a strong partner to Global Franchise Lead(s) and Therapeutic Area Heads, including PM/GPL partnership, assignments, performance, oversight of inflections points, decisions, acceleration opportunities, escalation, critical risk management, delivery of disease area strategies, and management/evolution of GPT Operating Model
Hold team members accountable for Program and Project Management responsibilities, including development/execution of ADP and indication-specific plans, integrated project schedules, critical path assessment, scenario planning, timeline visualizations
Directly lead asset and indication level risk management; ensure delivery by GPT sub-teams and execution teams (e.g., study teams)
Provide leadership for team readiness for governance
Ensure delivery and adherence to established PM systems, processes, and ways of working
Oversee GPT budget and resource health
Ensure team members’ data and outputs meet PPM data quality expectations
Maintain close oversight for key development inflection points within portfolio
Serve as a thought partner to challenge ADPs and identify acceleration opportunities

Responsibilities

Direct oversight for a group of PMs assigned to asset programs (GPT) and early/late development projects (asset indications) of varying scope and complexity
Deliver and grow PM team members as subject matter experts (SMEs)
Serve as interim Program Management Lead as business needs require, shaping and delivering Target Product Profile (TPP) and Asset Development Plan (ADP) for assigned asset(s) and indications

Skills

Program Management

Line Management

Portfolio Management

Project Execution

Therapeutic Area Oversight

Asset Development Plan

Target Product Profile

Global Program Lead Partnership

Cell Therapy

Strategic Partnership

Bristol-Myers Squibb

Develops and delivers biopharmaceutical medicines

About Bristol-Myers Squibb

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

New York City, New YorkHeadquarters

1887Year Founded

$33,706.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Risks

Increased competition in oncology from emerging biotech firms like ArsenalBio.

BMS's lawsuit over the 340B Drug Pricing Program may lead to regulatory challenges.

Rapid AI and digital tech evolution may pose integration challenges for BMS.

Differentiation

BMS focuses on innovative cancer treatments through collaborations like ArsenalBio for T cell therapies.

The company emphasizes digital health technologies, enhancing clinical trial management and patient engagement.

BMS offers both innovative and generic medicines, increasing affordable healthcare solutions.

Upsides

BMS's partnership with Medidata enhances clinical research processes and patient outcomes.

The collaboration with AI Proteins advances novel miniprotein-based therapeutics, expanding therapeutic modalities.

BMS's global license agreement with BioArctic expands its portfolio in neurodegenerative diseases.

Land your dream remote job 3x faster with AI

Try Jobo Free